Evaluation of albutoin as an antiepileptic drug

James J. Cereghino, Joseph T. Brock, John C. Van Meter, J. Kiffin Penry, Lawrence D. Smith, Pearl Fisher, Jonas Ellenberg

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


A double-blind, controlled study of efficacy and bioavailability of the investigational antiepileptic drug albutoin was performed in a population of institutionalized patients whose seizures were not completely controlled by therapeutic dosages, as determined by serum levels, of combinations of currently available antiepileptic drugs. Albutoin did not appear to be as effective as diphenylhydantoin, primidone, or phenobarbital in controlling seizure frequency. Serum albutoin levels indicated the drug was poorly absorbed at dosages up to 1,200 mg per day. Nausea, anorexia, and weight loss were significant problems in over 10% of the patients receiving 1,200 mg of albutoin per day. Few controlled studies are available as models for evaluating the efficacy of antiepileptic drugs. With minor modifications, the double-blind study design described could be used as a means o f rapidly (21 days) evaluating drugs as antiepileptic agents.

Original languageEnglish (US)
Pages (from-to)406-416
Number of pages11
JournalClinical pharmacology and therapeutics
Issue number4
StatePublished - Apr 1974

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Evaluation of albutoin as an antiepileptic drug'. Together they form a unique fingerprint.

Cite this